骨髓增生异常综合征患者的健康相关生活质量与脆弱性:一项美国全国性研究
该前瞻性队列纳入449例因血细胞减少接受骨髓评估的患者,基线健康相关生活质量在各诊断间相似;在骨髓增生异常综合征患者中,脆弱者及预后较差者健康相关生活质量更差,且脆弱性对生活质量的影响超过疾病风险。
要点
- 449例疑似骨髓增生异常综合征患者基线健康相关生活质量在各诊断间相似。
- 骨髓增生异常综合征患者中,脆弱者PROMIS疲劳均分56.0 vs 非脆弱者49.5,P<.001。
- 低、中、高危疾病EQ-5D-5L均分分别为73.4、72.7、64.1,P=.005。
核心结论
- 导致骨髓增生异常综合征评估的血细胞减少与相似的健康相关生活质量相关,与最终诊断无关,但脆弱者健康相关生活质量更差。
- 在骨髓增生异常综合征患者中,较低危疾病与较好健康相关生活质量相关,但该关系在脆弱者中消失,首次显示脆弱性对健康相关生活质量的影响超过疾病风险。
研究设计与样本
- 美国国立心肺血液研究所资助的骨髓增生异常综合征自然史研究,为前瞻性队列,纳入因血细胞减少接受疑似骨髓增生异常综合征检查的患者。
- 未治疗患者接受骨髓评估并经中心组织病理学复核,分为骨髓增生异常综合征、骨髓增生异常综合征/骨髓增殖性肿瘤、意义未明特发性血细胞减少、原始细胞<30%的急性髓系白血病或「At-Risk」。
- 健康相关生活质量数据在入组时采集,包括骨髓增生异常综合征特异性骨髓增生异常生活质量量表(QUALMS);脆弱性采用脆弱老年人调查评估。
- 基线健康相关生活质量评分来自449例骨髓增生异常综合征、骨髓增生异常综合征/骨髓增殖性肿瘤、原始细胞<30%的急性髓系白血病、意义未明特发性血细胞减少或「At-Risk」患者。
主要发现
- 449例骨髓增生异常综合征、骨髓增生异常综合征/骨髓增殖性肿瘤、原始细胞<30%的急性髓系白血病、意义未明特发性血细胞减少或「At-Risk」患者的基线健康相关生活质量评分在各诊断间相似。
- 在骨髓增生异常综合征中,脆弱参与者健康相关生活质量更差,例如患者报告结局测量信息系统(PROMIS)疲劳均分56.0 vs 49.5,P<.001。
- 在骨髓增生异常综合征中,预后较差者健康相关生活质量更差,例如低、中、高危疾病的Euroqol-5维度-5水平(EQ-5D-5L)均分分别为73.4、72.7、64.1,P=.005。
- 在脆弱骨髓增生异常综合征参与者中,多数长时间体力活动有困难(88%),如步行四分之一英里有困难(74%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Health-related quality of life (HRQoL) and vulnerability are variably affected in patients with myelodysplastic syndromes (MDS) and other cytopenic states; however, the heterogeneity of these diseases has limited our understanding of these domains. The National Heart, Lung, and Blood Institute-sponsored MDS Natural History Study is a prospective cohort enrolling patients undergoing workup for suspected MDS in the setting of cytopenias. Untreated patients undergo bone marrow assessment with central histopathology review for assignment as MDS, MDS/myeloproliferative neoplasm (MPN), idiopathic cytopenia of undetermined significance (ICUS), acute myeloid leukemia (AML) with <30% blasts, or "At-Risk." HRQoL data are collected at enrollment, including the MDS-specific Quality of Life in Myelodysplasia Scale (QUALMS). Vulnerability is assessed with the Vulnerable Elders Survey. Baseline HRQoL scores from 449 patients with MDS, MDS/MPN, AML <30%, ICUS or At-Risk were similar among diagnoses. In MDS, HRQoL was worse for vulnerable participants (eg, mean Patent-Reported Outcomes Management Information Systems [PROMIS] Fatigue of 56.0 vs 49.5; P < .001) and those with worse prognosis (eg, mean Euroqol-5 Dimension-5 Level [EQ-5D-5L] of 73.4, 72.7, and 64.1 for low, intermediate, and high-risk disease; P = .005). Among vulnerable MDS participants, most had difficulty with prolonged physical activity (88%), such as walking a quarter mile (74%). These data suggest that cytopenias leading to MDS evaluation are associated with similar HRQoL, regardless of eventual diagnosis, but with worse HRQoL among the vulnerable. Among those with MDS, lower-risk disease was associated with better HRQoL, but the relationship was lost among the vulnerable, showing for the first time that vulnerability trumps disease risk in affecting HRQoL. This study is registered at www.clinicaltrials.gov as NCT02775383.
引用
- Abel GA, Hebert D, Lee C, et al. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Adv. 2023. PMID: 37146263. doi:10.1182/bloodadvances.2022009000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。